ArticleInternational journal of clinical oncology2012
Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.
Article in International journal of clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis.Journal of ovarian research · 2020Pooled it
- Identification of serum peptide biomarkers for cholangiocarcinoma diagnosis and staging via MALDI-TOF MS and LC-MS/MS.British journal of cancer · 2026Article
- Serum peptide biomarkers by MALDI-TOF MS coupled with machine learning for diagnosis and classification of hepato-pancreato-biliary cancers.Scientific reports · 2025Article
- MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer.Biomedicines · 2023Article
- Serum peptidomic screening identified circulating peptide biomarkers predictive for preeclampsia.Frontiers in cardiovascular medicine · 2022Article
- Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test.Cancers · 2021Article
- Recent advancements in fabrication of nanomaterial based biosensors for diagnosis of ovarian cancer: a comprehensive review.Mikrochimica acta · 2020Review
- Detection of Epithelial Ovarian Cancer using C8Magnetic Bead Separation and MALDI-TOF Plasma Proteome Profiling in Egyptian Females.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Mass spectrometry-based proteomics techniques and their application in ovarian cancer research.Journal of ovarian research · 2018Review
- MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.BMC cancer · 2017Article
- Article
- Profiling plasma peptides for the identification of potential ageing biomarkers in Chinese Han adults.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study was to search for potential protein biomarkers in serum for diagnosis of ovarian cancer, by use of proteomic fingerprint techniques.
methodMALDI-TOF-MS was combined with magnetic beads to profile and compare serum protein spectra from 40 ovarian cancer patients and from 60 healthy controls.
resultsThe tree analysis model of potential cancer biomarkers was constructed with Biomarker Patterns software on the basis of three identified biomarkers (5486, 6440, and 13720 Da), resulting in excellent discrimination between the ovarian cancer and non-cancer in our tests. The sensitivity was 90% and the specificity was 86.7%. In a blind test the sensitivity was 88% and the specificity was 83.3%.
conclusionThe results suggested that biomarkers for ovarian cancer diagnosis in serum could be identified by MALDI-TOF-MS combined with the use of magnetic beads. The use of combined biomarkers would further enable powerful and reliable diagnosis of ovarian cancer with high sensitivity and specificity.
Indexed as
Identifiers
21638024What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.